Patents by Inventor Mark A. Reddish

Mark A. Reddish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multivalent streptococcal vaccine compositions and methods for use
    Patent number: 7270827
    Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: September 18, 2007
    Assignees: University of Tennessee Research Foundation, ID Biomedical Corporation of Washington
    Inventors: Mark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
  • Multivalent streptococcal vaccine compositions and methods for use
    Publication number: 20030143245
    Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.
    Type: Application
    Filed: October 28, 2002
    Publication date: July 31, 2003
    Applicant: University of Tennessee Research Corporation
    Inventors: Mark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
  • Lipid-modified muc-1 derivatives
    Patent number: 6600012
    Abstract: A method for generating a mixture of activated T-cells by combining a plurality of peripheral blood lymphocytes (PBLs) with an antigen-loaded liposome to produce antigen-loaded PBLs, and combining the antigen-loaded PBLs with a naive, anergic or memory T-cell, to produce an activated T-cell. Such activation is carried out in vivo or in vitro. The antigen-loaded PBLs and activated T-cells, prepared according to the methods of invention, have use as cellular vaccines for treatment of cancer and viral diseases.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: July 29, 2003
    Assignee: Biomira, Inc.
    Inventors: Babita Agrawal, Mark J. Krantz, Mark A. Reddish, B. Michael Longenecker